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The ability to computationally predict the effects of toxic 
compounds on humans could help address the deficiencies of 
current chemical safety testing. Here, we report the results from 
a community-based DREAM challenge to predict toxicities of 
environmental compounds with potential adverse health effects 
for human populations. We measured the cytotoxicity of 156 
compounds in 884 lymphoblastoid cell lines for which genotype 
and transcriptional data are available as part of the Tox21 1000 
Genomes Project. The challenge participants developed algorithms 
to predict interindividual variability of toxic response from genomic 
profiles and population-level cytotoxicity data from structural 
attributes of the compounds. 179 submitted predictions were 
evaluated against an experimental data set to which participants 
were blinded. Individual cytotoxicity predictions were better than 
random, with modest correlations (Pearson’s r < 0.28), consistent 
with complex trait genomic prediction. In contrast, predictions 
of population-level response to different compounds were higher 
(r < 0.66). The results highlight the possibility of predicting 
health risks associated with unknown compounds, although risk 
estimation accuracy remains suboptimal.
The ability to predict a toxic response in a population could help 
establish safe levels of exposure to new compounds and identify 
individuals at increased risk for adverse health outcomes. Current risk 
assessment does not account for individual differences in chemical 
exposure response. Furthermore, standard safety testing is performed 
on a small fraction of existing environmental compounds1 and uses 
animal models that are costly, time-consuming and do not always 
reflect human safety profiles2. Algorithms that provide accurate in silico 
predictions of safety risks in humans could provide an accurate 
and cost-effective tool to identify potential health risks to specific 
populations. However, previous prediction algorithms have been 
limited by lack of data about population variability and difficulties 
in extrapolating from model organisms3,4.
The development of high-throughput in vitro toxicity studies using 
human-derived cell models5 and rapidly decreasing sequencing costs 
have enabled large, genetically distinct populations to be character-
ized. High-throughput in vitro systems have been successfully used to 
assess changes in transcriptional6,7 and phenotypic8 traits in response 
to compound exposure. Furthermore, genomically characterized cell 
lines that decrease nongenetic sources of variation9,10 have been used 
to identify genetic variants and transcripts associated with both in vitro 
and clinical responses to drug exposures11,12. These technologies 
enable systematic toxicity screening of a wide range of compounds in 
human cell lines to assess population-level responses and to examine 
variation in risk profiles across individuals13.
This work formed part of an open community challenge within the 
Dialogue on Reverse Engineering Assessment and Methods (DREAM) 
framework14,15. Participating researchers were asked to predict inter-
individual variability in cytotoxic response based on genomic and 
transcriptional profiles (subchallenge 1) and to predict population-
level parameters of cytotoxicity across chemicals based on structural 
attributes of compounds (subchallenge 2). Cellular toxicity was 
assessed for 156 compounds across lymphoblastoid cell lines derived 
from 884 individuals5 from nine distinct geographical subpopulations 
across Europe, Africa, Asia and the Americas (Fig. 1)16. Genetic17 
and transcriptional data18 from these cell lines were available as part 
of the 1000 Genomes Project. The data set has twice the number of 
cell lines and three times the number of compounds compared with 
the previous largest study19. We evaluated the submitted state-of- 
the-art modeling approaches to benchmark current best practices in 
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predictive modeling. Furthermore, the challenge identified algorithms 
that were able to predict, with better than random accuracy, indi-
vidual and population-level response to different compounds using 
only genomic data. Although these results represent an improvement 
over previous attempts to predict cytotoxicity response, substantial 
improvements in prediction accuracy remain critical.
RESULTS
Challenge participation
213 people from more than 30 countries registered to participate in 
the NIEHS-NCATS-UNC (National Institute of Enivronmental Health 
Sciences–National Center for Advancing Translational Sciences–
University North Carolina) DREAM Toxicogenetics challenge. 
Participants were provided with a subset of the data to train models 
over a 3-month period, and models were evaluated on a second subset 
of test data to which the participants were blinded (Fig. 1). The train-
ing data included (i) a measure of cytotoxic susceptibility per cell line 
(EC10, the dose for which a 10% decrease in viability occurred) for 106 
compounds tested across 487 cell lines; (ii) genotypes for all 884 cell 
lines; (iii) RNA-seq-based quantification of gene transcripts for 337 cell 
lines, and (iv) structural attributes of all 156 compounds. 34 research 
teams submitted a total of 99 predictions of interindividual variation 
in response to subchallenge 1, and 23 research teams submitted a total 
of 80 predictions of population-level toxicity parameters in response 
to subchallenge 2. The challenge offered the unique opportunity to 
compare performance across a wide variety of state-of-the-art methods 
(Supplementary Table 1 and Supplementary Predictive Models) for 
the prediction of cytotoxic response to environmental compounds.
Subchallenge 1: prediction of interindividual variation
Models were evaluated based on their ability to predict EC10 values in 
a blind test set comprising EC10 values measured in 264 cell lines that 
were not included in the training set. Prediction accuracy was scored 
using two metrics: Pearson correlation (r), which evaluates the linear 
dependence between predicted and measured EC10 values, and a 
rank-based metric, the probabilistic C-index (pCi)15, which takes into 
account the probabilistic nature of the gold standard due to technical 
sources of noise in the associated measures by evaluating the concord-
ance of cell line cytotoxicity ranks. Scoring analyses were limited to 91 
compounds, excluding 15 compounds for which no effect on cytotox-
icity was observed across the entire population, in order to avoid the 
introduction of noise in the ranking (Supplementary Fig. 1). For each 
metric, overall team ranks were calculated by ranking teams separately 
for each compound and then averaging across compounds.
We first assessed whether predictions were significantly better 
than random by comparing the average r (Fig. 2a) and the average pCi 
(Fig. 2b), computed across compounds for each submission with the cor-
responding null model of randomly empirically generated EC10 values. 
Out of the 99 submissions, the null hypothesis of randomly generated 
predictions could be rejected (false discovery rate (FDR) < 0.05, 
which automatically corrects for multiple hypotheses) for 46 sub-
missions using r, 47 submissions using pCi and for 42 submissions 
using both metrics. The average values over all compounds for r and 
pCi were quite modest (maximum value 0.07 and 0.51, respectively) 
suggesting that cytotoxic response to chemical exposure is not, in 
general, well predicted based on single-nucleotide polymorphism 
(SNP) data. Although average predictive ability was low, perform-
ance was not uniform across compounds. Variability in predictive 
performance across compounds ranged from −0.21 to 0.28 for 
r values and from 0.45 to 0.56 for pCi (Fig. 3a and Supplementary 
Fig. 2). We tested whether cytotoxicity of each compound could 
be predicted better than chance. For each compound, predicted 
EC10 values for all teams were compared with the null random 
model. This analysis verified that predictions are significantly better 
than random for most of the compounds (55 out of the 91 compounds; 
Wilcoxon rank sum test, P < 0.05), even if performances for some 
compounds are very poor. The ranking of best performing teams 
was shown to be robust with respect to the compounds used for 
scoring (Supplementary Fig. 3).
Prediction algorithms were also evaluated for their ability to 
categorically classify responses as cytotoxic or nontoxic using an EC10 
threshold of 1.25 (as defined based on the classification of response 
curves described in Online Methods). 91 of 99 submissions achieved 
average AUC-ROC (area under the curve of a receiver operating 
characteristic) above 0.9, indicating that binary classification is much 
easier to predict than exact EC10 values.
We next assessed the contribution to prediction quality of RNA 
sequencing (RNA-seq) data, which were available for only a subset of 
cell lines. Overall, predictions were significantly better in the 97 cell 
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Figure 1 The NIEHS-NCATS-UNC DREAM Toxicogenetics Challenge 
overview. The cytotoxicity data used in the challenge consist of the EC10 
data generated for 884 lymphoblastoid cell line in response to 156 
common environmental compounds. Participants were provided with a 
training set of cytotoxicity data for 620 cell lines and 106 compounds 
along with genotype data for all cell lines, RNA-seq data for 337 cell lines 
and chemical attributes for all compounds. The challenge was divided 
into two independent subchallenges: in subchallenge 1, participants were 
asked to predict EC10 values for a separate test set of 264 cell lines in 
response to the 106 compounds (only 91 toxic compounds were used for 
final scoring); in subchallenge 2, they were asked to predict population 
parameters (in terms of median EC10 values and 5th (q05) to 95th (q95) 
interquantile distance) for a separate test set of 50 compounds.
©
20
15
N
at
ur
e 
A
m
er
ic
a,
 
In
c.
 
 
A
ll 
rig
ht
s 
re
se
rv
ed
.
nature biotechnology   VOLUME 33 NUMBER 9 SEPTEMBER 2015 935
A n A ly s i s
lines with available RNA-seq data (Fig. 4, paired t-test, P < 10−16 for 
both r and pCi), which corresponds to a high effect size (Cohen’s 
d equal to 1.6, derived from t-statistics). These results are consistent 
with a recent report that gene expression is more predictive of drug-
induced cytotoxicity than genetic variation in cancer cell lines15.
Best performing method for subchallenge 1
The best performing method for prediction of interindividual varia-
tion in cytotoxic response was able to predict with maximum r = 0.23 
(average r = 0.05) and maximum pCi = 0.55 (average pCi = 0.51). As 
with the scoring analyses, this approach also omitted the 15 com-
pounds that failed to induce a cytotoxic response from the analysis. 
Figure 5a shows the workflow of the prediction procedure for this 
method, which included steps for dimension reduction, prediction 
and cross-validation. A set of 0.15 M SNPs was selected for inclu-
sion in this analysis using two approaches: (i) nonsynonymous SNPs 
within any gene as well as SNPs close to any gene defined by 2 kb 
upstream and 500 bp downstream regions; (ii) remaining SNPs if 
located within or close to gene members of the 41 KEGG20 gene sets 
(Supplementary Table 2) documented in the MSigDB database21 
to represent cell cycle, cell death or cancer biology, or if they dem-
onstrated correlation (P < 0.05) with the expression of at least one 
local gene based on the RNA-seq data (eQTL analysis). Information 
contained within this SNP set was then compiled into ten ‘genetic 
clusters’ using k-means clustering based on the first three principal 
components obtained by multidimensional scaling analysis22. The 
resultant ‘genetic cluster’ variable was highly representative of known 
geographic subpopulations (Fig. 5b), but also contained additional 
information not directly represented by each subpopulation. This 
variable was used to build a model of cytotoxicity for each compound 
using the Random Forest algorithm in conjunction with sex, geo-
graphic area and experimental batch. Cross-validation was carried 
out to choose parameters for clustering and to select methods for 
filtering SNPs. In the final scoring phase, this prediction approach 
achieved the best performance among dozens of submitted models, 
judged by the experimentally obtained true-response data. Details of 
this modeling approach are discussed further in Online Methods and 
Supplementary Predictive Models.
Figure 2 Significance of predictions.  
(a–d) Submissions are compared with the 
null hypothesis for subchallenge 1 (a,b) and 
subchallenge 2 (c,d). For each metric used for 
scoring (Pearson correlation (a) and pCi (b) for 
subchallenge 1, and Pearson correlation (c) and  
Spearman correlation (d) for subchallenge 2),  
performances shown for submissions are 
computed compound by compound and then 
averaged across compounds. The null hypothesis 
is generated for random predictions computed 
by random sampling, compound by compound, 
from the training set. (e,f) Performance of 
individual predictions (first boxplot, in red) 
is compared with performances of randomly 
aggregated predictions (wisdom of the crowds, in 
green) and with the aggregation of all predictions 
(last black bar). Performances are shown in 
terms of average Pearson correlation computed 
between predicted and measured values 
separately for each compound. Predictions were 
aggregated by averaging them. To aggregate only 
independent predictions, only one submission 
for each team was considered as the average of 
all predictions submitted by the team.
Subchallenge 2: prediction of population-level parameters
Predictions of population-level parameters were scored using both 
Pearson correlation (r) and Spearman correlation (rs), with an 
approach similar to the previous subchallenge. For both statistics, the 
global performance of each submission was assessed by averaging cor-
relations computed separately for median EC10 values, representing 
a ‘typical’ cytotoxicity response, and the difference between the 95th 
and 5th percentiles (interquantile range) for EC10 values, representing 
a measure of population dispersion.
The comparison with the null model of random predictions (Fig. 2c,d) 
was performed to assess the statistical significance of compound 
predictions. Of the 80 submitted predictions, the null hypothesis of 
randomly generated predictions was rejected (FDR < 0.05) for 13 pre-
dictions using average r and for 17 using average rs. For 13 predictions, 
the null hypothesis was rejected when both metrics were considered. 
A similar outcome was observed when using Fisher’s method to assess 
the significance of individual submissions. Again, the ranking of 
best performing teams was shown to be robust with respect to the 
compounds used for scoring (Supplementary Fig. 4).
The average cytotoxicity (median EC10) of compounds appeared 
to be easier to predict (r ranged from −0.31 to 0.66; rs ranged from 
−0.29 to 0.72) than the variability in the response (interquantile 
range) of the population (r ranged from −0.22 to 0.37; rs ranged from 
−0.14 to 0.48; Supplementary Fig. 5).
Best performing method for subchallenge 2
The overall evaluation criterion for subchallenge 2 combined the 
prediction of median and interquantile range. The best performing 
method was able to predict the median and interquantile distance with 
r (and rs) equal to 0.52 (0.45) and 0.37 (0.40). The workflow used by this 
method (Fig. 5c), consisted of four major steps: feature selection, group 
identification, model development and test compound prediction. 
Features were selected from structural attributes of chemicals (step 1) 
derived in three ways and compared: CDK23 and SiRMS24 descriptors 
(both provided by the Challenge organizers) and Dragon descriptors25. 
Chemical descriptors were normalized separately and those descriptors 
that correlated with toxicity were used for training the models. The 
models using the Dragon descriptors achieved the best performance 
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in both cross-validation and final scoring. In 
Step 2, compounds were categorized into four 
groups based on hierarchical clustering of their 
EC10 profiles across 487 cell lines. Random 
Forest models of cytotoxicity built sepa-
rately for each compound group (Fig. 5c,d) 
were used to select features specific to pre-
diction in that group, using all compounds 
to train the model. These models were used 
for predicting new compounds (Fig. 5c,e) as 
follows. For each new compound, toxicity was 
estimated using a weighted average of predic-
tions from all four group-specific models, 
where weights were determined by similar-
ity to each of the compound clusters. The 
similarity measure considered the distance 
to the cluster in the group-specific descrip-
tor space, as well as the probability of being 
in the cluster using an additional classifica-
tion model. The above modeling approaches 
were applied to predict both the median EC10 
values and the interquantile range. For median EC10, cell-line spe-
cific predictions were generated using separate models and then aver-
aged. For interquartile distance, a set of models was built to directly 
fit the measured interquantile distance for each compound. Further 
details of this modeling approach are discussed in Online Methods 
and Supplementary Predictive Models. Although this method 
was the best overall performer, other methods such as KSPA (see 
team Austria, Supplementary Predictive Models), provided more 
accurate prediction of the median cytotoxicity with r and rs equal 
to 0.65 and 0.72, respectively.
Predictability of compounds
Compounds were clearly separated into three clusters based on the 
accuracy of cytotoxicity predictions (Fig. 3a): a cluster of compounds 
for which predictions were high across all models (14 compounds), a 
cluster of compounds for which predictions were low across all models 
(17 compounds) and a cluster of compounds for which predictions 
varied across models. This separation was consistent between the two 
metrics used to evaluate performances (Supplementary Fig. 2). We 
next tested for features that could distinguish between compounds in 
the high-versus-low predictability clusters. Several chemical descriptors 
distinguished between high-versus-low predictability compounds and 
are listed in Supplementary Table 3. Notably, the Lipinski rule26 (i.e., a 
rule of thumb to evaluate drug similarity) was among these distinguish-
ing features. As expected, compounds in the highly predictive cluster 
had lower pooled variance (thus are less noisy) than those in the poorly 
predicted cluster (one tailed t-test, P = 0.027). Contrary to expectation, 
compounds in the high-versus-low predictability clusters did not 
differ with regard to the distribution of cytotoxic response across the 
population in terms of median and interquantile range (Wilcoxon rank 
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Figure 3 Performances of predictions.  
(a,b) Predictions were compared to the gold 
standard based on Pearson correlation for 
subchallenge 1 (a) and subchallenge 2 (b). The 
heatmap in a illustrates performances of all 
predictions for all compounds used for evaluation; 
predictions are ranked as in the final leaderboard 
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Figure 4 Advantages of using RNA-seq data. 
(a,b) Performances of predictions for cell  
lines for which RNA-seq data were available 
were compared against performances of 
predictions for cell lines for which RNA-seq 
data were not available. Pearson correlation 
and pCi were computed for each compound; 
the comparison shows that predictions for  
cell lines for which RNA-seq data were 
available are significantly better (paired t-test, 
P << 10−10). All predictions are included  
in the analysis regardless of the actual use  
of the RNA-seq data.
©
20
15
N
at
ur
e 
A
m
er
ic
a,
 
In
c.
 
 
A
ll 
rig
ht
s 
re
se
rv
ed
.
nature biotechnology   VOLUME 33 NUMBER 9 SEPTEMBER 2015 937
A n A ly s i s
sum test, P = 0.65 and 0.68, respectively) nor to estimated heritability of 
compound cytotoxicities (P = 0.33; Supplementary Fig. 6). However, 
we observed that, when performing a principal component analysis 
on the cytotoxicity data (distributions centered to zero and scaled to 
unit variance for each compound), we could distinguish between the 
compounds with high and low predictability (Supplementary Fig. 7), 
indicating that the predictability was at least partially due to the cyto-
toxic profile of the compounds across the population.
Additionally, there was a clear difference in the shape of the distri-
butions of the cytotoxic response across these two compound classes 
(Supplementary Fig. 8). In particular, highly predictable compounds 
tended to be characterized more frequently by a multimodal distribution 
(35% of highly predictable compounds, 0% of poorly predictable com-
pounds, Hartigans’s dip test for unimodality P < 0.05). The enrichment 
of multimodal distributions in highly predictable compounds suggests 
that algorithms are able to distinguish well when there are groups of 
individuals showing a different response to the same compound, rather 
than when the response follows a unimodal distribution. The principal 
component analysis allowed us also to estimate the predictive power that 
can be expected for new compounds. A linear support vector machine 
showed an accuracy of 66% (leave-one-out bootstrapping 5,000 times).
Wisdom of crowds
Previous DREAM challenges15,27,28 have observed that aggregation of 
predictions, which leverage the collective insight of all participants, 
can provide a more robust estimate than any individual prediction. 
We verified that, when applied to the test sets used for the challenge, 
the averaged aggregation across predictions within this study per-
formed on par with top individual predictions for both subchallenge 1 
(Supplementary Fig. 9a) and subchallenge 2 (Supplementary Fig. 9f). 
It is interesting to note that adding poor methods to an ensemble 
degrades the aggregate performance to a lesser degree than the gain 
resulting from adding good methods. For example, in subchallenge 1, 
the inclusion of the worst five individual predictions (whose correlations, 
from 0 to −0.015, had a range of 0.015) caused only a 5.55% decrease 
of performances based on Pearson correlation, whereas the inclusion 
of the top five individual predictions (whose correlations also had 
a range of 0.015, but from 0.03 to 0.045) caused a 21.17% increase 
(Supplementary Fig. 9d,e). The same trends have been observed in 
other analyses of ensemble methods27.
To robustly test whether aggregate model performance was 
consistently better at prediction relative to individual predictions, 
we next performed 200 iterations of an analysis in which optimized 
aggregate models were built using half of the test data and evaluated 
for performance using the remaining test data. Optimized aggregate 
models performed significantly better than the best individual 
prediction (paired t-test, P < 2.2 × 1016 for subchallenge 1 and 0.027 
for subchallenge 2; Supplementary Fig. 9b,g). The optimal aggregate 
prediction outperformed the top individual prediction for all runs 
in subchallenge 1 and for 88.5% of the runs in subchallenge 2. 
Although optimized aggregate models built from the most accurate 
individual predictions have the best performance, in practice it is 
not possible to obtain an objective performance estimate for each 
model before analysis. For this reason, we also built an unsupervised 
aggregate model by combining a random selection of individual 
predictions. As a general trend, unsupervised aggregate models 
exhibited improved performance with respect to randomly selected 
individual predictions (Fig. 2e,f). Hence, as a general rule, it is prefer-
able to aggregate efforts generated using different approaches even 
when the performance of the individual algorithms is unknown. 
Indeed, for both subchallenges 1 and 2, the aggregation of all pre-
dictions outperforms 87% of individual team predictions.
Characteristics of modeling approaches
We assessed modeling methodologies used within the challenge by 
surveying participants regarding their selection of input data, pre-
processing methodologies for data reduction, prediction algorithms 
and techniques for model validation (Fig. 6). All predictions used at 
least one of the data sources provided by the organizers. Notably, some 
models performed well using only the sex/ancestry covariates in the 
absence of genomic data (subchallenge 1, Team ranked 4th). Most 
of the teams, including the best performing teams, also integrated 
1.32 M SNPs
Annotation
of genes
Curated chemical structures
(training set compounds)
Chemical descriptor proles
Toxicity-related descriptors
Step 3
Step 1 Step 2
Step 4
New compounds Predicted toxicity
Toxicity = ∑i = 1Weighti × Predictioni
Group-specic models
Toxicity responses
Multimodal distributions
0.6 M SNPs
1) KEGG pathway
2) RNA-seq data
0.15 M SNPs
MDS plot
of PLINK
First 3 PCs
Kmeans
clustering
yes no
1) Whether to lter with KEGG
    pathway or/and RNA-seq data
2) Number of PCs to use
3) Number of genetic clusters to form
(RandomForest with
gender, population
and batch as covariates)
Genetic clusters
C
ro
ss
 v
al
id
at
io
n
Prediction
a
b
c
d
e
JPT 
CHB
YRI
LWK
GBR
CEU
TSI
MXL
CLM
1 2 3 4 65 7 8 109
80
60
40
20
0
100
Group1
specic features
Model 1
Model i, i = 1–4
Distance to model (d)
Classication
model
Training
samples
Membership = probability Membership = 0
Weighti Predictioni
d < DistAP?
Group1 Group2 Group3 Group4
vs and
4
H
H
H
H
H
H
N N
H
Figure 5 Best performing method  
subchallenge 1 and subchallenge 2. The 
prediction procedure of the best performing 
team of subchallenge 1. (a) Workflow of  
prediction for subchallenge 1. (b) Heatmap  
of number of cell lines in each category of 
“genetic cluster” (1–10, x axis) and geographic 
subpopulation (y axis). (c) Modeling workflow 
used by team QBRC for Toxicogenetics  
Challenge subchallenge 2. The model starts 
from deriving potential toxicity-related features 
by comparing response data and chemical 
descriptor profiles (step 1) and classifying 
compounds based on their toxicity responses 
(step 2). Then, group-specific models are built 
based on group-specific chemical features and 
the entire training set (step 3). Finally, the 
toxicity of a new compound is calculated as 
a weighted average of the predicted toxicities 
from each group-specific model (step 4).  
(d) In step 3, differentially distributed features 
and all training samples are used to develop 
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information from external sources into their 
models (24% for subchallenge 1 and 47% 
for subchallenge 2). A variety of methodo-
logical algorithms representing the state of 
the-art in the modeling field were applied 
in both subchallenges. No methodologies 
for data reduction, predictive modeling or 
model validation used in this challenge out-
performed the others in any obvious man-
ner (Supplementary Fig. 10), suggesting 
that performance was dependent mainly 
on strategy for methodological application 
rather than on algorithmic choice.
DISCUSSION
The results of the NIEHS-NCATS-UNC-
DREAM Toxicogenetics Challenge demon-
strate that modeling algorithms were able to 
predict cytotoxicity traits based on genetic 
profiles with higher than random accuracy, 
although results were modest. The methods 
developed for subchallenge 1 are likely to 
be even more useful in future settings, as 
decreasing sequencing costs means that 
larger training sets will be available to achieve 
higher predictive accuracy.
Accurate predictions of population-level cytotoxicity could help 
to establish safe environmental exposure limits. Therefore, we tested 
whether population-level cytotoxicity could be predicted based on 
the structural attributes of compounds (subchallenge 2). Participants 
were able to robustly predict both mean toxicity and population 
variability in cytotoxicity based entirely on chemical attributes of 
compounds. These results demonstrate that predictive algorithms may 
be able to provide real-world benefit in environmental risk assessment 
and suggest an opportunity to incorporate structural predictions into 
hazard assessments of new compounds.
The ability to predict interindividual variability in cytotoxic response 
(subchallenge 1) is consistent with predictive performances for complex 
genetic traits such as height29. Comparable predictive performances 
were also observed in a recent DREAM analysis comparing algorithms 
that predicted cellular response to cancer agents15. Because each 
individual SNP describes only a small portion of overall variation in 
response, the ability to accurately predict phenotype, or even to detect 
true genetic signal in large-scale genomic analysis, requires very large 
sample sizes30,31. Downsampling analyses suggest that predictability 
would increase with additional samples (Supplementary Fig. 11).
The complex nature of the EC10 cytotoxic phenotype, which is 
a statistic that can be influenced by often high levels of technical 
variation9, may also decrease prediction power. Indeed, we observed 
that algorithms were able to broadly classify compounds as cytotoxic 
or noncytotoxic more accurately than they could predict cytotoxicity. 
We also observed that cytotoxic predictability varied across com-
pounds although we could not identify a clear pattern as to which 
characteristics improve predictability.
Regardless of these limitations, prediction rules identified within best 
performing algorithms can be leveraged to advance future efforts within 
this field regarding data collection and prediction analysis. In particu-
lar, the best performing team in subchallenge 1 developed a novel data 
processing approach that incorporated prior biological knowledge into 
their machine-learning methodology by clustering individual cell lines 
based on variants located in a set of presumed biologically relevant loci. 
Figure 6 Overview of methods and data used 
to solve the challenges. Overview of the input 
data, data reduction techniques, prediction 
algorithms and model validation techniques 
used by participants to solve the challenge. 
Participants were asked to fill out a survey 
in order to be included in this publication 
as part of the NIEHS-NCATS-UNC Dream 
Toxicogenetics challenge consortium; only data 
for teams that filled out the survey are shown 
here. Each row corresponds to a submission, 
and they are ordered based on the final rank 
for subchallenge 1 and subchallenge 2, 
respectively. Data originate from 75 filled-out 
surveys for subchallenge 1 (of 99 submissions) 
and 51 filled-out surveys for subchallenge 2  
(of 80 submissions). This corresponds to 21  
(of 34) teams for subchallenge 1 and  
12 (of 23) for subchallenge 2.
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The resultant clusters were broadly representative of geographically dis-
tinct subpopulations but included additional information. This approach 
may be generally useful in predicting complex traits based on genetic 
variant data. The prediction approaches developed for subchallenge 2 
could be generalized to predict and rationalize chemical compounds’ 
biological properties from chemical structures. The proposed model 
incorporated the population-level structures in toxicity profiles into 
traditional, quantitative, structure-activity relationship models.
A unique aspect of this study is that it focuses on the use of con-
stitutional genetic variation to predict toxicity response. Although 
some studies support the idea that transcriptomic profiles can provide 
higher predictive performance than genetic profiles—and, indeed, 
we observed improved predictive performance with the availability 
of baseline transcriptional data—the use of transcriptional data has 
often been upon perturbation, which is not applicable within our 
framework of environmental risk assessment. As such, the use of 
genetic profiles to predict variation in response—across individuals 
and across compounds—on the population level provides a tool that 
can be applied within real-world applications.
Overall, our analyses assessed the capability of computational 
approaches to provide meaningful predictions of cytotoxic response to 
environmental compound exposure using genetic and chemical struc-
ture information. The models developed within this project would 
require higher accuracy to provide actionable information at the level 
of an individual. However, for prioritization of compounds, this study 
provides statistically significant evidence for the ability to predict toxic 
effects on populations using a stringent evaluation methodology.
METHODS
Methods and any associated references are available in the online 
version of the paper.
Accession codes. All data used for the challenge are available in 
Synapse (syn1761567).
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
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ONLINE METHODS
Data description. A schematic of the challenge is outlined in Figure 1. The 
cytotoxicity data used in the challenge consist of the estimated effective con-
centrations that induced a 10% decrease in viability (i.e., the EC10) generated 
for 884 lymphoblastoid cell lines in response to 156 common environmental 
compounds. Participants were provided with a training set of cytotoxicity data 
for 620 cell lines and 106 compounds along with genotype data for all cell lines, 
RNA-seq data for 337 cell lines and chemical attributes for all compounds. 
Primary data generation and other details on the cytotoxicity screening 
are detailed in Abdo et al.5 available in open access at: http://ehp.niehs.nih.
gov/1408775/. A brief description of the data is provided below. A total of four 
toxicity phenotyping, genomic, genotyping and chemical attribute data sets 
were available for this challenge. Descriptions of each data set can be found in 
the annotation files associated with each data set supplied through the DREAM 
website (https://www.synapse.org/#!Synapse:syn1761567/wiki/56224).
(1) Chemicals. Chemicals were a subset of the National Toxicology 
Program’s 1408 chemical library as detailed in Xia et al.32 and were selected 
to broadly represent chemicals found in the environment and consumer 
products. A small number of pharmaceuticals was included as well, but the 
focus of this experiment was on environmental toxicants. Chemicals were 
dissolved in dimethyl sulfoxide (DMSO) to prepare 20 mM stock concen-
trations, and then diluted in DMSO to provide final concentrations ranging 
from 0.33 nM to 92 µM. We fit all chemicals and concentrations, including 
duplicate samples for 8 chemicals, and positive and negative controls for each 
cell line to a single 1,536-well plate.
(2) Cell lines. We acquired the immortalized lymphoblastoid cell lines from 
Coriell. We aimed to represent human genetic diversity and thus selected 
cell lines from nine populations across the globe from Europe, the Americas, 
Asia and Africa. These included the Han Chinese in Beijing, China (CHB); 
Japanese in Tokyo, Japan (JPT); Luhya in Webuye, Kenya (LWK); Yoruban in 
Ibadan, Nigeria (YRI); Utah residents with European ancestry (CEU); British 
from England and Scotland (GBR); Tuscans in Italy (TSI); Mexican ancestry 
in Los Angeles, California (MXL); and Colombians in Medellín, Colombia 
(CLM). Cell lines were selected to reflect unrelated individuals by remov-
ing all instances of first-degree relatives. Within each population, cell lines 
were included from both males and females. Cell lines were randomly divided 
into five screening batches with equal distribution of populations and gender. 
Approximately 65% of the cell lines were seeded for repeat analysis on multiple 
plates (2–3 plates per batch and/or between batches).
(3) Cytotoxicity profiling. Screening was performed in 1,536-well plate 
format. The negative control was DMSO at 0.46% vol/vol; the positive con-
trol was tetra-octyl-ammonium bromide (46 µM). We used the CellTiter-
Glo Luminescent Cell Viability assay (Promega) to assess intracellular ATP 
concentration, a marker for viability/cytotoxicity, at 40 h post treatment. We 
used a ViewLux plate reader (PerkinElmer) to detect luminescent intensity. 
Cytotoxicity data were divided into two parts for training and external valida-
tion of the models. The former contained individual EC10 values in a 487 cell 
line × 106 compound matrix. The latter contained population-level summary 
statistics of EC10 values per compound in a 106 compound × 3 statistics matrix. 
EC10 values were calculated from concentration-response exposure data for 
each chemical across all 884 cell lines and were normalized relative to the 
positive/negative controls. The EC10 value is defined as the concentration 
at which intracelluar ATP content was decreased by 10% and was estimated 
for each cell line by normalizing data to vehicle-treated cells and then fit-
ting normalized concentration-response curves to a three parameter logistic 
regression model where maximum response was fixed to −100% and minimum 
response was derived from the response of the lowest three concentrations, 
with the exclusion of outliers as defined by >2 s.d. If the compound had less 
than 10% effect over the range of concentrations used in the experiment, the 
EC10 was set to 100 µM to represent a “no observable adverse effect level.” 
EC10 values were batch corrected using Combat33 and then replicate values 
per individual were averaged. Batch information is provided in the covariate 
file, although data have already been corrected for this technical source of 
variation. Data providers verified that EC10 and EC50 values are reasonably 
correlated. However, only EC10 values were used for the challenge, as this is the 
most interesting measure for low-dose toxic response and highest relevance 
for susceptible subpopulations.
(4) Genotype data. Approximately 1.3 million SNPs are provided for each 
individual. For 761 cell lines, these SNPs were directly genotyped using 
the Illumina HumanOmni2.5 platform. For the remaining 123 unrelated 
individuals, the available sequencing data were used to impute the missing 
SNPs, using either HapMap3 genotypes for these individuals, or sequence 
data, using MACH software and the reference set for imputation. SNPs with 
a call rate below 95%, MAF < 0.01, strong evidence against Hardy-Weinberg 
disequilibrium (P < 10−6) were excluded from this data set, leaving a final set 
of 1,327,016 SNPs.
(5) RNA sequencing. RNA sequencing data were available for 337 of 
the cell lines (representing the CEU, GBR, TSI and YRI subpopulations) as 
data set E-GEUV-1 in the ArrayExpress repository. The mapped reads files 
(BAM format) were downloaded and IsoDOT was used to count the reads 
of each nonoverlapping exon, which has been preprocessed in IsoDOT 
library files. Read counts for each gene were generated by summing the read 
counts for all of that gene’s exons. Data are provided as raw gene counts 
for 46,256 transcripts.
(6) Chemical attributes. Each compound is described by quantitative 
structural attributes as developed using two standard methodologies for the 
purpose of providing a standardized description of structural properties that 
are common across chemicals and can be used to model structure-based 
commonalities in cytotoxicity. Attributes include 160 chemical descriptors 
calculated using the Chemistry Development Kit (CDK)23. In addition, 9,272 
chemical descriptors were generated for each compound using the Simplex 
representation of molecular structure (SIRMS)24. In this process, each mole-
cule is represented as a system of tetratomic fragments with fixed composition, 
structure, chirality and symmetry as described here. Data were not further 
processed or normalized.
Web-based resource and challenge rules. The challenge was hosted on 
Synapse34, a cloud-based platform for collaborative scientific data analysis. 
Synapse was used to distribute challenge data and to track participant agree-
ment to the appropriate data usage conditions (main challenge web page 
https://www.synapse.org/#!Synapse:syn1761567). Synapse was used also to 
run a real-time leaderboard during the first phase of the challenge, where 
participant could submit their prediction on a test set (133 cell lines) that was 
then released as part of the training set for the final phase of the challenge, and 
receive real time feedback on their performances (Supplementary Fig. 12).
For the final submissions, challenge participants created Synapse projects 
(https://www.synapse.org/#!Synapse:syn1840307/wiki/67255) containing their 
predictions (maximum five predictions per team) together with the code used 
to derive them and wikis in which participants describe their methods in 
prose and figures. To assure reproducibility of the challenge, the organizers of 
submissions ran the code of the best performing methods. All data are stored 
in synapse and are available in Synapse (https://www.synapse.org/#!Synapse:
syn1761567/wiki/56224).
Supplementary Figures, Supplementary Tables, Supplementary Predictive 
Models and Supplementary Code are is also available in Synapse as an 
interactive resource https://www.synapse.org/#!Synapse:syn1840307.
Software and statistical methods. R (v3.1) was used for scoring and for post-
challenge analysis and False Discovery Rate (FDR) was computed using the 
Benjamini–Hochberg procedure. R (v2.15) and plink (v1.07) were used by the 
best performing team of subchallenge 1. R (v2.15) and Dragon (v5.5) were 
used by the best performing team of subchallenge 2. All relevant code has been 
provided as Supplementary Code and can also be found online (https://www.
synapse.org/#!Synapse:syn1840307/wiki/231104). The file includes: a) scoring 
functions, b) code used to generate supplementary figures, c) code submitted 
by participants and used to generate predictions.
Selection of training and test set. For both subchallenges, the data set was 
divided in training and test set using stratified random sampling to guarantee 
that extreme responses were included in both training and test data. More in 
details, for subchallenge 1, the data set was clustered in N groups based on EC10 
profiles, where N is the number of individuals in the test set. One individual 
is then selected from each group to be part of the test set. This guarantees 
that strong and weak responses were present in both the training and the 
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test sets, which is also more representative of the task of predictive genomics. 
The same approach was used for subchallenge 2, but with clustering by 
compounds instead of by individuals.
Scoring algorithm for subchallenge 1. For each metric (i.e., Pearson corre-
lation and prob C-index), teams were ranked separately for each compound 
and then the average rank was computed, for each team, across compounds, 
providing a final rank for each metric. Teams were finally ranked (final rank) 
based on the average of the rank computed for each metric (mean rank-
ing). Only 91 out of 106 compounds were used for final scoring as 15 com-
pounds were shown to have no toxicity across the human cell population 
(Supplementary Fig. 1a). Since the aim of the challenge is the prediction of 
how individual cell lines differently respond to each compound, compounds 
for which the response is the same across all the population are not interesting 
in this context and were therefore excluded from the evaluation to avoid 
including noise in the scoring metric.
Significance and robustness of subchallenge 1. Significance of prediction for 
individual compounds. By comparing the distribution of submissions with 
respect to the null model of randomly predicted EC10 values, we verified that 
predictions are significantly better then random for 55 of 91 compounds 
(Wilcoxon sum rank test, P < 0.05) if we consider r and pCi separately, and 
for 59 of 91 compounds if we consider compounds for which the hypothesis 
of equal distribution is rejected for at least one metric. To assess whether lack 
of predictability was universal across submissions, we repeated this analysis 
within the subset of 25 submissions with the best prediction for each com-
pound. In this case, the alternative hypothesis is accepted for all 91 compounds 
for both r and pCi.
Significance of predictions based on ranking. The mean ranking across 
compounds was compared with the empirical null distribution of 100,000 
randomized mean rankings, derived by randomly ranking teams for each com-
pound and then computing the randomized mean ranking (Supplementary 
Table 4). Of the 99 predictions, the null model could be rejected (t-test, 
FDR < 0.05) for 17 predictions, considering the mean ranking computed based 
on Pearson correlation, and for 17 predictions, when considering pCi. For 
15 predictions, the null model was rejected considering both metrics.
Robustness analysis. To assess the robustness of the final team rank with 
respect to the compounds used for scoring, we recomputed the score multiple 
times by randomly masking each time, data for 10% of the compounds. 
In Supplementary Figure 3, we compared the distribution of the mean ranking 
and of the final rank obtained by all teams and verified that the best sub-
mission is reliably ranked first as it is significantly on top with respect to all 
the other submissions (one-sided Wilcoxon signed-rank test, FDR < 10−10). 
The robustness analysis also shows that all of the top six submissions are 
statistically different.
Classification problem. Considering the inherent variances in the measured 
EC10 values, the model performances were reevaluated for their significance in 
predicting the activity outcome of a compound in a cell line (i.e., cytotoxic or non-
toxic), instead of the exact EC10 value. As shown in Supplementary Figure 13a, 
most of the compounds in the test set were either active/cytotoxic (43%) 
in all of the cell lines or inactive/nontoxic (16%) across all of the cell lines, 
whereas each cell line showed a well-balanced number of active/inactive calls. 
To evaluate overall model performance at classifying active and inactive com-
pounds, for each model submission, AUC-ROC values were calculated first 
for each cell line then averaged across all cell lines (Supplementary Fig. 13b, 
red line). With a few exceptions, most model submissions (91 out of 99) per-
formed well with average AUC-ROC values >0.9. To further assess model 
performance, model sensitivity (recall) was calculated for compounds that 
were active across all cell lines to test the model’s capacity at correctly making 
active calls, and specificity was calculated for compounds that were inactive 
across all cell lines to test the model’s capacity at correctly making inactive 
calls. For this analysis, the active EC10 cutoff was determined by comparing the 
experimental EC10 values of all test set compounds to their cytotoxic/nontoxic 
classifications. An EC10 of 1.25 µM was chosen as the optimal cutoff for classi-
fying a compound as active in a cell line. The average sensitivity and specificity 
measures calculated for all model submissions are shown in Supplementary 
Figure 13b. Most model submissions achieved good sensitivity (Supplementary 
Fig. 13b; green line) in predicting active compounds and good specificity 
(Supplementary Fig. 13b; purple line) in predicting inactive compounds with 
84 out of the 99 submissions achieving >90% average sensitivity and 91 submis-
sions achieving >90% average specificity.
Evaluation of model performance. Compounds were assigned one of the 
four categories, true positive (TP), false positive (FP), true negative (TN) and 
false negative (FN), based on their activity observed in the assay and model 
predicted activity according to the following scheme.
Predicted/experimental  Cytotoxic  Nontoxic
EC10 ≤ active cutoff  TP   FP
EC10 > active cutoff  FN   TN
The numbers of TP, FP, TN and FN calls were counted at various EC10 cutoffs 
and the AUC-ROC was calculated for each compound in each cell line. The 
ROC curve is a plot of sensitivity against 1-specificity, where sensitivity is 
defined as TP/(TP+FN) and specificity defined as TN/(FP+TN). A perfect 
model would have an AUC-ROC of 1 and an AUC-ROC of 0.5 or lower 
indicates that the model predictions are not better than random.
Best performing method for subchallenge 1. We evaluated the effect of 
removing any one of the four predictors used in the random Forest algorithm 
on the prediction. Supplementary Figure 14 shows that removing any of the 
four predictors leads to a worse prediction accuracy measured by Pearson cor-
relation. We also investigated whether the filtering step with KEGG pathway 
and RNA-seq data gives any improvement in prediction accuracy by randomly 
sampling 0.15 million SNPs from the 0.61 million SNPs selected from the first 
step of feature selection or directly using the 0.61 million SNPs to generate 
principal components. Indeed, Supplementary Figure 14 shows that 
both methods lead to a mean Pearson correlation that is even smaller than 
a prediction model that does not include the “genetic cluster” variable. 
In conclusion, our results suggest that the four variables (sex, population, 
experimental batch and “genetic cluster”) all contribute to the prediction 
accuracy and that the second round of filtering with KEGG pathway and RNA-
seq data helps to generate a “genetic cluster” variable that carries meaningful 
information regarding compound toxicity.
Scoring algorithm for subchallenge 2. Predictions were ranked separately for 
each metric (i.e., Pearson correlation and Spearman correlation) by comput-
ing the average rank of each team for the predicted median and interquantile 
distance. The final rank was thus computed based on the average of the rank 
computed using the two metrics (mean ranking).
Significance and robustness of subchallenge 2. Significance of predictions 
based on Fisher’s method. The statistical significance of predictions was 
verified by combining, using Fisher’s method, the P-value computed separately 
for the performances of each submission in predicting the median and the 
interquantile distance. Performances are above what is expected at random 
(FDR < 0.05) for 26 submissions when considering Pearson correlation, for 39 
submissions when considering Spearman correlation, and for 24 submissions 
when considering both metrics (Supplementary Table 5).
Robustness analysis. The robustness analysis (Supplementary Fig. 4), com-
puted as described for subchallenge 1, showed that the best performing team 
is robustly ranked first with all five submissions outperforming submissions 
from other teams (one-sided Wilcoxon signed-rank test, FDR < 10−10). As 
shown from the FDR analysis, the top two submissions are not statistically 
distinguishable.
Best performing method for subchallenge 2. To predict chemical toxicities 
from chemical profiles, we developed computational models with four steps. 
The first step is feature selection. The curated chemical structure (provided by 
the organizer in Structure Data Format (SDF)) was used to generate Dragon25 
descriptors for each compound. The derived descriptor matrices were range 
scaled to 0~1, and those with low variance (s.d. < 10−6) were excluded. For 
any pair of highly correlated descriptors (Pearson correlation, P > 0.95), one 
descriptor was removed randomly. The descriptors were then filtered based 
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on their correlation to compounds’ cytotoxicity (EC10 values). There are 67 
descriptors that are significantly (Pearson correlation, P < 0.05) correlated to 
EC10 values in >70% of the cell lines.
The second step is to evaluate the toxicity distributions of the compounds, 
and to determine the compound groups based on their toxicity profiles. We 
divided the 106 compounds into four groups based on hierarchical clustering 
of their EC10 profiles across 487 cell lines.
The third step is to develop group-specific models (Fig. 5c). For each group 
identified in step 2, we used ANOVA to select features that are specific for 
compounds in the group versus compounds in the remaining groups. Then, 
the values of the selected features for all training compounds (91 compounds 
with measurable toxicity values) were used as the training data. Therefore, 
there are four Random Forest models that are specific to each cluster of com-
pounds (model M1, M2, M3, M4).
The final step is to apply the models for predicting new compounds 
(Fig. 5d). For each new compound, we estimated its toxicity by a weighted 
average of its predictions from all four group-specific models. The weights 
were determined by its similarity to each of the compound clusters. The 
similarity involves calculating the compound’s distance to the cluster in 
the group-specific descriptor space, as well as its probability of being in the 
cluster using a classification model. If the compound’s distance to one cluster 
is smaller than a distance threshold, we think that the cluster-specific model 
is appropriate to predict the new compound, and the weight is proportional 
to its probability of being in that group. Otherwise, we think the model is 
inappropriate to predict the new compound, and its weight for predicting 
this specific compound would be 0. The distance threshold is determined by 
the applicability domain described by Zhen and Tropsha35 (with parameter 
z = 2). In certain cases, where the new compound is out of the threshold for all 
four group-specific models, we predicted its activity using the entire training 
set and all the descriptors.
We apply the above modeling approaches to estimate both the median 
EC10 values and the interquartile distance for new compounds, but with small 
modifications. To predict a compounds’ median EC10 value, we built separate 
models to fit EC10 values measured from individual cell lines. We then derived 
the median EC10 value from the predicted cell-line-specific EC10 values. To 
predict a compounds’ interquartile distance, we built a single set of models to 
fit the measured interquartile distance directly.
Predictability of compounds. We compared the cytotoxic response of all 
individuals to the two groups of compounds as shown in Supplementary 
Figure 8; in this case the null hypothesis of equal mean of the two groups 
is now rejected (P < 2.2 × 10−16) and, notably, there is a clear difference in 
the shape of the two distributions. The first possible reason for the bimodal 
distribution of EC10 values of highly predictable compounds is that this group 
of compounds show very high or very low toxicity in all of the population; 
however, this is not the case because, if we test for multimodality the median 
EC10 values of highly predictable compounds, we verify that the distribution 
is unimodal (Hartigans’s dip test, P = 0.70). The second possible reason is that 
highly predictable compounds are the ones that show multimodal distribu-
tion across the population; applying the Hartigans’s dip test for unmodality 
on all compounds (distribution of EC10 values across individuals), we verify 
that 35.71% (5 of 14) of the highly predictable compounds have a multimodal 
distribution (P < 0.05, Supplementary Fig. 8b for two examples), whereas 0% 
(0 of 17) of the poorly predictable compounds have a multimodal distribution 
(they all have unimodal distribution; Supplementary Figure 8c for two 
examples). The percentage of multimodal distributions is 10% for the remain-
ing compounds (6 of 60).
Noise in the data. The distribution of the pooled variance for compounds 
with high predictability is slightly but significantly shifted to the left with 
respect to the distribution for compounds with low predictability (one tailed 
t-test, P = 0.027). Thus, as expected, noisy compounds are in general harder 
to predict with respect to compounds with a lower pooled variance.
Survey data analysis. We received responses for 75 submissions (out of 99) 
for subchallenge 1 and for 51 submissions (out of 80) for subchallenge 2. This 
corresponds to 21 (out of 34) teams for subchallenge 1, and 14 (out of 23) for 
subchallenge 2. An overview of the information provided by the survey is 
shown in Figure 6. The effect of used data and methods on the performances 
of submissions is shown in Supplementary Figure 10 in terms of average 
Pearson correlation. To deal with the fact that each team submitted up to five 
submissions that might not be independent of each other, predictions using 
the same data and methods (based on the information from the survey) were 
averaged and considered as one prediction. Using this approach, we obtained 
49 independent submissions for subchallenge 1 and 28 for subchallenge 2. 
Data and methods listed as “others” in Supplementary Figure 10 and Figure 
6 are reported in Supplementary Table 6.
Input data used for predictions. To solve subchallenge 1, 89% of the partici-
pants who replied to the survey, used the SNPs data provided by the organizers 
either alone or along with other data using additional sources (e.g., pathway 
information, GO terms) to filter them. RNA-seq data were used for almost half 
(47%) of the submissions and this was shown to provide an overall improve-
ment of performances. Only a minority of the participants (16%) also included 
in their predictive model information about chemical descriptors.
For subchallenge 2, most submissions (78%) did not take into account any 
genetic information to predict the cytotoxicity of new compounds. As for 
the chemical features, about 76% made use of at least one of the chemical 
descriptors provided by the organizers (CDK and SiRMS), but many teams 
(45%) included in addition or exclusively information from other sources like 
ChEMBL36 and PubChem37 public databases or different chemical descriptors 
like Dragon25 or ECFP38 (see Supplementary Table 6 for the full list).
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Erratum: Prediction of human population responses to toxic compounds by 
a collaborative competition
Federica Eduati, Lara M Mangravite, Tao Wang, Hao Tang, J Christopher Bare, Ruili Huang, Thea Norman, Mike Kellen,  
Michael P Menden, Jichen Yang, Xiaowei Zhan, Rui Zhong, Guanghua Xiao, Menghang Xia, Nour Abdo, Oksana Kosyk,  
the NIEHS-NCATS-UNC DREAM Toxicogenetics Collaboration, Stephen Friend, Allen Dearry, Anton Simeonov, Raymond R Tice,  
Ivan Rusyn, Fred A Wright, Gustavo Stolovitzky, Yang Xie, & Julio Saez-Rodriguez
Nat. Biotechnol. 33, 933–940 (2015); published online 10 August 2015; corrected after print 1 October 2015
In the version of this article initially published, in the HTML only, all authors names were incorrectly included in the main author list, and several 
authors names were repeated. The authors have now added 12 additional authors to the list of “Other participants in the NIEHS-NCATS-UNC 
DREAM Toxicogenetics Collaboration,” including Alok Jaiswal, Antti Poso, Himanshu Chheda, Ismeet Kaur, Jing Tang, John-Patrick Mpindi, 
Krister Wennerberg, Natalio Krasnogor, Samuel Kaski, Tero Aittokallio, Petteri Hintsanen and Suleiman Ali Khan. Names in this list that were also 
in the list of “top-performing teams” have been deleted. In addition, affiliation number 3 (Univ. Texas) has been added to Xiaowei Zhang’s name 
in the main author list. The errors have been corrected in the HTML and PDF versions of the article.
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